Baseline characteristics for patients in the intervention (n = 7) and control group (n = 7).
HCM
DILATED CARDIOMYOPATHY, ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY, ISCHEMIC HEART DISEASE, LONG QT SYNDROME, IHD, HYPERTROPHIC CARDIOMYOPATHY
Summarized by mean (standard deviation) or number (percent).ARVC: Arrhythmogenic right ventricular cardiomyopathy, DCM: Dilated cardiomyopathy, HCM: Hypertrophic cardiomyopathy, IHD: Ischemic heart disease, IVF: Idiopathic VFLQTS: Long QT syndrome.From baseline to six-weeks follow-up a mean dose of 61 mg (SD 28) MRA and a mean dose of potassium supplement of 2,678 mg (SD 1,048) ~ 36 mmol were prescribed to the participants in the intervention group. There was an increase in p-K in all patients in the intervention group and three out of seven patients reached target levels of p-K between 4.5–5.0 mmol/l.One patient was diagnosed with another illness independent of the trial between the six-week- and the six-month follow-up. Due to subsequent diagnostic nuclear isotope imaging that would have affected the WBC measurement, the patient was excluded from the six-month follow-up.At baseline, mean p-K was 3.8 mmol/l (SD 0.1) in the intervention group and 3.8 mmol/l (SD 0.2) in the control group (P = 0.44). Baseline TBK was 1.44 g/kg (SD 0.23) in the intervention group and 1.56 g/kg (SD 0.17) in controls (P = 0.33).